Cancer BiologyThe EMBO JournalPeer-reviewed
SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis
Rema Iyer, Anagha J. Deshpande, Aditi Pedgaonkar…·Aniruddha J. Deshpande
This study identifies SUMO2 as a selective vulnerability in synovial sarcoma, showing that SUMO2 inhibition reverses SS18-SSX-driven gene expression and impairs tumor growth.
6 citations